Nasdaq Edges Higher; Neovasc Shares Jump
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
Dow Tumbles 300 Points; Morgan Stanley Beats Q4 Views
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping over 300 points on Tuesday.
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ: ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angi
Reported Late Wednesday, Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
Angion Biomedica Q2 EPS $(0.30) Up From $(0.58) YoY
Angion Biomedica (NASDAQ:ANGN) reported quarterly losses of $(0.30) per share. This is a 48.28 percent increase over losses of $(0.58) per share from the same period last year.
HC Wainwright Downgrades Angion Biomedica
Last month, Angion Biomedica Corp (NASDAQ:ANGN) discontinued the JUNIPER Phase 2 dose-finding trial of ANG-3070 in primary proteinuric kidney diseases, specifically focal…